¼¼°èÀÇ ºñħ½ÀÀû °ü»óµ¿¸Æ À̹Ì¡ ½ÃÀå
Non-invasive Coronary Imaging
»óǰÄÚµå : 1788207
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 274 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,229,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,687,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ºñħ½ÀÀû °ü»óµ¿¸Æ À̹Ì¡ ½ÃÀåÀº 2030³â±îÁö 5¾ï 3,060¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 3¾ï 9,230¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ºñħ½ÀÀû °ü»óµ¿¸Æ À̹Ì¡ ½ÃÀåÀº 2030³â¿¡´Â 5¾ï 3,060¸¸ ´Þ·¯¿¡ ´ÞÇϸç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 5.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®Çϰí ÀÖ´Â ºÎ¹®ÀÇ ÇϳªÀÎ ½ÉÀå ÃÊÀ½ÆÄ °Ë»ç´Â CAGR 3.5%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 2¾ï 480¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½ÉÀå ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 6.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 690¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ºñħ½ÀÀû °ü»óµ¿¸Æ À̹Ì¡ ½ÃÀåÀº 2024³â¿¡ 1¾ï 690¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1¾ï 400¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 7.9%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.6%¿Í 5.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ºñħ½ÀÀû °ü»óµ¿¸Æ À̹Ì¡ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ºñħ½ÀÀû °ü»óµ¿¸Æ À̹Ì¡ÀÌ ½ÉÇ÷°ü Áø´ÜÀÇ ÆÇµµ¸¦ ¾î¶»°Ô ¹Ù²Ü °ÍÀΰ¡?

ºñħ½ÀÀû °ü»óµ¿¸Æ À̹Ì¡Àº Ä«Å×Å͸¦ ÀÌ¿ëÇÑ ½Ã¼ú ¾øÀ̵µ ¾ÈÀüÇÏ°í ½Å¼ÓÇϸç Á¤È®ÇÑ °ü»óµ¿¸ÆÁúȯ(CAD) Æò°¡ ¹æ¹ýÀ» ÀÓ»óÀÇ¿¡°Ô Á¦°øÇÔÀ¸·Î½á ½ÉÇ÷°ü Áø´ÜÀÇ Àü¸Á¿¡ Çõ¸íÀ» ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ °ü»óµ¿¸Æ Á¶¿µ¼úÀº È¿°úÀûÀÌÁö¸¸ ħ½ÀÀû Ư¼ºÀ¸·Î ÀÎÇØ ÀáÀçÀûÀÎ Ç÷°ü ¼Õ»ó, Á¶¿µÁ¦¿¡ ´ëÇÑ ¾Ë·¹¸£±â ¹ÝÀÀ, °Ë»ç ÈÄ È¸º¹ ½Ã°£ µî ȯÀÚ À§Ç輺ÀÌ Å®´Ï´Ù. ¹Ý¸é, °ü»óµ¿¸Æ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(CCTA), ½ÉÀå ÀÚ±â°ø¸í¿µ»ó(CMR), ¾çÀüÀÚ¹æ»ç´ÜÃþÃÔ¿µ(PET) µîÀÇ ºñħ½ÀÀû ±â¼úÀº °ü»óµ¿¸Æ Ç÷°üÀÇ °íÇØ»óµµ ½Ã°¢È­¸¦ °¡´ÉÄÉ Çϸ鼭µµ ½Ã¼úÀÇ À§Ç輺À» ³·Ãß°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ÇöóÅ© ÃàÀûÀ» °¨ÁöÇϰí, ÇùÂøÀ» Æò°¡Çϰí, Àü¹ÝÀûÀÎ ½ÉÀå ±â´ÉÀ» Æò°¡ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ȯÀÚ ÀÔÀå¿¡¼­´Â °Ë»ç ½Ã°£ ´ÜÃà, ºÒÆí°¨ °¨¼Ò, ÀÔ¿ø ±â°£ ´ÜÃà µîÀÇ Å« ÀÌÁ¡ÀÌ ÀÖÀ¸¸ç, ÀÇ»ç ÀÔÀå¿¡¼­´Â »ó¼¼ÇÑ ÇØºÎÇÐÀû, ±â´ÉÀû µ¥ÀÌÅÍ¿¡ ´ëÇÑ Á¢±ÙÀ» ÅëÇØ ´õ ¸¹Àº Á¤º¸¿¡ ±â¹ÝÇÑ Ä¡·á ¹æÄ§À» °áÁ¤ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºñħ½ÀÀû ¿µ»ó Áø´Ü ÅøÀº Áõ»óÀÌ ³ªÅ¸³ª±â ÈξÀ Àü¿¡ ÀáÀçÀûÀÎ Á׻󵿸ưæÈ­ÁõÀ» °¨ÁöÇÒ ¼ö ÀÖÀ¸¸ç, ¿¹¹æÀû ½ÉÀ庴Çп¡¼­ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. CT¿¡¼­ ¾òÀº ºÐȹÇ÷·ù¿¹ºñ·Â(FFR-CT)°ú °°Àº ¹æ¹ýÀ» ÅëÇÑ ±â´ÉÀû Æò°¡ÀÇ ÅëÇÕÀº ÇØºÎÇÐÀû ¿µ»ó°ú »ý¸®Àû ÀλçÀÌÆ® »çÀÌÀÇ °£±ØÀ» ¸Þ¿ö ÇãÇ÷À» À¯¹ßÇÏ´Â º´º¯À» º¸´Ù Á¤È®ÇÏ°Ô ½Äº°ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ½ÉÇ÷°ü°è ÁúȯÀÌ ¿©ÀüÈ÷ Àü ¼¼°è »ç¸Á¿øÀÎ 1À§ÀÎ ¸¸Å­, Á¶±â ¹ß°ß°ú Áúº´ °ü¸®¿¡ ÀÖÀ¸¸ç, ºñħ½ÀÀû ¿µ»ó Áø´ÜÀÇ ¿ªÇÒÀº ¾ÕÀ¸·Î ´õ¿í Ä¿Áú °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Áø´ÜÀÇ Á¤È®¼º°ú È¿À²¼ºÀ» ³ôÀ̱â À§ÇÑ ±â¼úÀÇ ¿ªÇÒÀº ¹«¾ùÀΰ¡?

¿µ»ó Áø´Ü ±â¼úÀÇ ¹ßÀüÀº ºñħ½ÀÀû °ü»óµ¿¸Æ ¿µ»ó ¼Ö·ç¼ÇÀÇ ½Å·Ú¼º°ú äÅ÷üÀ» ³ôÀÌ´Â µ¥ ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. CT ½ºÄ³³ÊÀÇ ¹ßÀüÀ¸·Î ÃÔ¿µ ¼Óµµ°¡ »¡¶óÁö°í, ÇÇÆø¼±·®ÀÌ °¨¼ÒÇϰí, °ø°£ ÇØ»óµµ°¡ Çâ»óµÊ¿¡ µû¶ó °ü»óµ¿¸Æ CT ¾Þ±Û ÃÔ¿µÀº °ü»óµ¿¸Æ ÁúȯÀÌ ÀǽɵǴ ȯÀÚ¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â ÃÖÀü¹æ ÅøÀÌ µÇ¾ú½À´Ï´Ù. µ¿½Ã¿¡ ½ÉÀå MRI´Â ȯÀÚ¿¡°Ô Àü¸®¹æ»ç¼±À» Á¶»çÇÏÁö ¾Ê°í ½É±ÙÀÇ °ü·ù, »ýÁ¸·Â, ¼¶À¯È­¸¦ Æò°¡Çϱâ À§ÇØ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀΰøÁö´É°ú ¸Ó½Å·¯´×ÀÌ ¿µ»ó Áø´Ü Ç÷§Æû¿¡ ÅëÇյǸ鼭 Áø´Ü Á¤È®µµ°¡ ´õ¿í Çâ»óµÇ¾ú°í, ´ë±Ô¸ð µ¥ÀÌÅÍ ºÐ¼®¿¡ ±â¹ÝÇÑ ÇùÂø ÀÚµ¿ °¨Áö, ÇöóÅ© Ư¼ºÈ­, À§Çèµµ °èÃþÈ­°¡ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ±â¼úÀº ¿öÅ©Ç÷ο츦 °£¼ÒÈ­ÇÏ¿© ¿µ»óÀÇÇаú Àü¹®ÀÇ¿Í ½ÉÀå Àü¹®Àǰ¡ º¸´Ù ºü¸£°í Àϰü¼º ÀÖ°Ô ½ºÄµÀ» ÇØ¼®ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. µà¾ó ¿¡³ÊÁö CT¿Í ±¤ÀÚ °è¼ö CT´Â Â÷¼¼´ë ¿µ»ó ±â¼ú Çõ½ÅÀ¸·Î, Á¶Á÷ ´ëºñ¸¦ °­È­ÇÏ°í °ü»óµ¿¸ÆÀÇ ½Ã°¢È­¸¦ ¹æÇØÇÏ´Â ¾ÆÆ¼ÆÑÆ®¸¦ °¨¼Ò½ÃÄÑ °ü»óµ¿¸ÆÀÇ ½Ã°¢È­¸¦ ¹æÇØÇÏ´Â ¾ÆÆ¼ÆÑÆ®¸¦ °¨¼Ò½Ãŵ´Ï´Ù. ¶ÇÇÑ ½ºÆ®·¹½º CMRÀ̳ª PET ½ºÄµ°ú °°Àº ±â´ÉÀû ¿µ»ó Áø´Ü ±â¼úÀº ½É±Ù Ç÷·ù ¹× °ü·ù Àå¾Ö¿¡ ´ëÇÑ ¸Å¿ì Á¤È®ÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÏ¿© Ç÷Çà Àç°Ç¼úÀÇ Çʿ伺À» ÆÇ´ÜÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀüÀÚÀǹ«±â·Ï(EHR) ¹× Ŭ¶ó¿ìµå ±â¹Ý °øÀ¯ ½Ã½ºÅÛ°úÀÇ »óÈ£¿î¿ë¼ºÀ» ÅëÇØ ¿øÈ°ÇÑ µ¥ÀÌÅÍ ÅëÇÕÀÌ °¡´ÉÇØÁ³À¸¸ç, ½Ã¼³ °£ ¼¼ÄÁµå ¿ÀÇǴϾð »ó´ãµµ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû µµ¾àÀº ´Ü¼øÈ÷ Á¤È®µµ¸¦ Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó, º¸´Ù ºü¸£°í, ȯÀÚ Ä£È­ÀûÀ̸ç, °íµµ·Î °³ÀÎÈ­µÈ Áø´Ü °æ·Î¸¦ À籸¼ºÇϰí ÀÖ½À´Ï´Ù.

ÀÓ»ó °üÇàÀÇ º¯È­¿Í ȯÀÚ ¼±È£µµ°¡ äÅÃÀ» ÃËÁøÇϰí Àִ°¡?

ºñħ½ÀÀû °ü»óµ¿¸Æ ¿µ»ó ÃÔ¿µ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡´Â ȯÀÚÀÇ ±â´ëÄ¡ º¯È­¿Í ÇÔ²² ÀÓ»óÀû °üÇàÀÇ º¯È­°¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¼øÈ¯±â³»°ú Àü¹®ÀÇ¿Í ÀϹÝÀǵéÀº ¾ÈÁ¤µÈ ÈäÅë°ú À§Çèµµ Æò°¡¸¦ À§ÇÑ 1Â÷ Áø´ÜÀ¸·Î ºñħ½ÀÀû ¿µ»ó Áø´ÜÀ» ÃßõÇÏ´Â °æÇâÀÌ ÀÖÀ¸¸ç, ƯÈ÷ ±× ÀÓ»óÀû À¯È¿¼ºÀ» Áö¿øÇÏ´Â ±Ù°Å°¡ Á¡Á¡ ´õ ¸¹¾ÆÁö°í ÀÖ½À´Ï´Ù. ¹Ì±¹½ÉÀåÇÐȸ(American College of Cardiology)¿Í À¯·´½ÉÀåÇÐȸ(European Society of Cardiology)¿Í °°Àº À¯¸íÇÑ ´ÜüÀÇ °¡À̵å¶óÀÎÀº ºÒÇÊ¿äÇÑ Ä§½ÀÀû ½Ã¼ú°ú ±×¿¡ µû¸¥ ÇÕº´ÁõÀ» ÁÙÀÏ ¼ö ÀÖ´Ù´Â °ÍÀ» Áõ¸íÇϰí ÀÖ½À´Ï´Ù. ºñħ½ÀÀû ½Ã¼úÀ» ÁöÁöÇÏ´Â °æÇâÀÌ °­ÇØÁö°í ÀÖ½À´Ï´Ù. ȯÀÚ ÀÔÀå¿¡¼­´Â ÆíÀǼº, ºÒ¾È°¨ °¨¼Ò, ºü¸¥ ȸº¹¿¡ ´ëÇÑ ¿ä±¸·Î ÀÎÇØ ºñħ½ÀÀûÀÎ ¿Ü·¡ ±â¹Ý Áø´ÜÀ» ¼±È£ÇÏ´Â °æÇâÀÌ ±× ¾î´À ¶§º¸´Ù °­ÇØÁö°í ÀÖ½À´Ï´Ù. À̴ ħ½ÀÀû °Ë»ç°¡ ´õ ³ôÀº À§ÇèÀ» ÃÊ·¡ÇÏ´Â °í·ÉÀÚ³ª ¿©·¯ ÇÕº´ÁõÀ» °¡Áø ȯÀÚ¿¡¼­ ƯÈ÷ °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºñħ½ÀÀû ´ë¾ÈÀº ¿ø°ÝÀÇ·á ¹× ¿ø°ÝÀÇ·á ¸ðµ¨¿¡¼­ º¸´Ù È®À强ÀÌ ¶Ù¾î³ª¸ç, Áø´Ü ¼­ºñ½º¸¦ Áö¹æÀ̳ª ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ªÀÇ È¯Àڵ鿡°Ôµµ È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ´ç´¢º´, ºñ¸¸, °íÇ÷¾Ð µî »ýȰ½À°ü °ü·Ã À§ÇèÀÎÀÚ Áõ°¡·Î ÀÎÇØ ƯÈ÷ ¹«Áõ»ó °íÀ§Ç豺¿¡¼­´Â ´õ ÀÏÂï, ´õ ÀÚÁÖ ½ÉÇ÷°ü °ËÁøÀ» ¹ÞÀ» Çʿ䰡 ÀÖ½À´Ï´Ù. º´¿ø°ú ¿µ»ó Áø´Ü¼¾Å͵éÀº ÀÌ·¯ÇÑ º¯È­¿¡ ´ëÀÀÇϱâ À§ÇØ ¸ÖƼ¸ð´Þ¸®Æ¼ À̹Ì¡ ½ºÀ§Æ®¿¡ ÅõÀÚÇϰí, ¿Ü·¡ Áø´ÜÀ» À§ÇÑ ¼øÈ¯±â°ú ¼­ºñ½º ¶óÀÎÀ» È®ÀåÇÏ´Â µî ´Ù¾çÇÑ ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¸ðµÎ ÀÇ·á ÇÁ·Î¹ÙÀÌ´õÀÇ Àü·«°ú ȯÀÚÀÇ »ç°í¹æ½ÄÀÌ Å©°Ô º¯È­Çϰí ÀÖÀ¸¸ç, Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ºñħ½ÀÀû °ü»óµ¿¸Æ À̹Ì¡ÀÌ Àå±âÀûÀ¸·Î äÅÃµÉ ¼ö ÀÖµµ·Ï ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºñħ½ÀÀû °ü»óµ¿¸Æ ¿µ»ó ½ÃÀåÀÇ ±Þ¼ºÀå ¿øµ¿·ÂÀº?

ºñħ½ÀÀû °ü»óµ¿¸Æ ¿µ»ó ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú Çõ½Å, ÀÓ»ó °æ·ÎÀÇ ÁøÈ­, ÀÇ·á ¼­ºñ½º Á¦°ø ½Ã½ºÅÛÀÇ º¯È­ µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °¡Àå Å« ¿øµ¿·Â Áß Çϳª´Â ħ½ÀÀû ½Ã¼ú ƯÀ¯ÀÇ À§Çè ¾øÀÌ °ü»óµ¿¸ÆÀÇ ÇØºÎÇÐÀû ±¸Á¶¿Í ±â´ÉÀ» ½Ç½Ã°£À¸·Î »ó¼¼ÇÏ°Ô ½Ã°¢È­ÇÒ ¼ö ÀÖ´Â À̹Ì¡ Ç÷§ÆûÀÇ ¹ßÀüÀÔ´Ï´Ù. ½ºÄ³³ÊÀÇ ¼Óµµ, À̹ÌÁö ÇØ»óµµ, ÈÄó¸® ¼ÒÇÁÆ®¿þ¾îÀÇ Áö¼ÓÀûÀÎ °³¼±À¸·Î ÀÌ·¯ÇÑ ¾ç½ÄÀÇ ÀÓ»óÀû À¯¿ë¼ºÀÌ Å©°Ô È®´ëµÇ¾ú½À´Ï´Ù. ÃÖÁ¾»ç¿ëÀÚ Ãø¸é¿¡¼­ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ºñħ½ÀÀû ¿µ»ó Áø´Ü¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³ô¿© ȯÀÚ¸¦ È¿À²ÀûÀ¸·Î ºÐ·ùÇÏ°í ºÒÇÊ¿äÇÑ ½ÉÀå Ä«Å×ÅÍ »ðÀÔÀ» ÁÙÀ̸ç Àü¹ÝÀûÀÎ Ä¡·áÀÇ ÁúÀ» Çâ»ó½Ã۱â À§ÇØ ºñħ½ÀÀû ¿µ»ó Áø´Ü¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â ƯÈ÷ CCTA³ª ½ÉÀå MRI¿Í °°Àº ºñħ½ÀÀû ½Ã¼úÀÇ Áø´ÜÀû, ¿¹ÈÄÀû °¡Ä¡¸¦ ÀÎÁ¤ÇÏ´Â ¾÷µ¥ÀÌÆ®µÈ ÀÓ»ó °¡À̵å¶óÀο¡ ÀÇÇØ Áö¿øµÇ°í ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ Çൿµµ ½ÃÀå ¿ªÇп¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, º¸´Ù ¾ÈÀüÇÑ Áø´Ü ¿É¼ÇÀ» Àû±ØÀûÀ¸·Î ã°í ¿¹¹æ °ËÁø ÇÁ·Î±×·¥¿¡ Âü¿©Çϴ ȯÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ AI Áö¿ø ¿µ»ó Áø´Ü ÅøÀÇ ÃâÇöÀ¸·Î »ý»ê¼ºÀÌ Çâ»óµÇ°í, Áø´ÜÀÇ ÆíÂ÷°¡ ÁÙ¾îµé°í, ÀÏ¹Ý °³¾÷Àdzª ºñÀü¹®°¡µµ °í±Þ ÇØ¼®À» º¸´Ù ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. º´¿ø ³×Æ®¿öÅ©¿Í ¿µ»ó Áø´Ü¼¾Å͵µ ÀÚ¿ø Ȱ¿ëÀ» ÃÖÀûÈ­Çϰí, Áø´Ü ÀÏÁ¤À» ´ÜÃàÇϰí, ȯÀÚ Ã³¸®·®À» °³¼±Çϱâ À§ÇØ ÀÌ·¯ÇÑ ±â¼úÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­¿¡ ¸ÂÃß¾î ¸¹Àº ±¹°¡ÀÇ Áø·áºñ º¸»ó ü°è°¡ Á¡Â÷ º¯È­Çϰí ÀÖÀ¸¸ç, ºñħ½ÀÀû ¿µ»ó Áø´ÜÀÌ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô °æÁ¦ÀûÀ¸·Îµµ ½ÇÇö °¡´ÉÇÑ ¼öÁØÀ¸·Î º¯È­Çϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î Àα¸ °í·ÉÈ­, ÁÂ½Ä »ýȰ½À°ü, ½Ä»ýȰÀÇ º¯È­ µîÀ» ¹è°æÀ¸·Î ¼±Áø±¹°ú °³¹ßµµ»ó±¹À» ¸··ÐÇÏ°í ½ÉÇ÷°ü ÁúȯÀÇ ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¤È®ÇÑ Á¶±â Áø´Ü Åø¿¡ ´ëÇÑ ¼ö¿ä°¡ ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ºñħ½ÀÀû °ü»óµ¿¸Æ À̹Ì¡ ½ÃÀåÀÇ ±Þ°ÝÇÑ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

¸ð´Þ¸®Æ¼(½ÉÀå ÃÊÀ½ÆÄ, ½ÉÀå ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ, ½ÉÀå ÀÚ±â°ø¸í¿µ»ó, ¹æ»ç¼º ÇÙÁ¾ ½ÉÀå ¿µ»ó); ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ÃÖÁ¾»ç¿ëÀÚ, ¿µ»ó Áø´Ü ¼¾ÅÍ ÃÖÁ¾»ç¿ëÀÚ, ¿¬±¸±â°ü ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ Å¥·¹ÀÌÆ®µÈ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Non-invasive Coronary Imaging Market to Reach US$530.6 Million by 2030

The global market for Non-invasive Coronary Imaging estimated at US$392.3 Million in the year 2024, is expected to reach US$530.6 Million by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Echocardiography, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$204.8 Million by the end of the analysis period. Growth in the Cardiac Computed Tomography segment is estimated at 6.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$106.9 Million While China is Forecast to Grow at 7.9% CAGR

The Non-invasive Coronary Imaging market in the U.S. is estimated at US$106.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$104.0 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Non-Invasive Coronary Imaging Market - Key Trends & Drivers Summarized

How Is Non-Invasive Coronary Imaging Changing the Game in Cardiovascular Diagnosis?

Non-invasive coronary imaging is revolutionizing the landscape of cardiovascular diagnostics, offering clinicians safer, faster, and highly accurate methods to assess coronary artery disease (CAD) without the need for catheter-based procedures. Traditional coronary angiography, while effective, involves significant patient risk due to its invasive nature, including potential vascular injury, allergic reactions to contrast agents, and post-procedure recovery time. In contrast, non-invasive techniques such as coronary computed tomography angiography (CCTA), cardiac magnetic resonance imaging (CMR), and positron emission tomography (PET) are enabling high-resolution visualization of coronary vessels with reduced procedural risk. These technologies have become pivotal in detecting plaque buildup, assessing stenosis, and evaluating overall heart function. Patients benefit significantly from quicker turnaround times, minimal discomfort, and reduced hospital stays, while physicians gain access to detailed anatomical and functional data that supports more informed treatment decisions. Additionally, the ability of non-invasive imaging tools to detect subclinical atherosclerosis-well before symptoms appear-has made them indispensable in preventive cardiology. The integration of functional assessment through methods like fractional flow reserve derived from CT (FFR-CT) is also bridging the gap between anatomical imaging and physiological insight, allowing more accurate identification of ischemia-causing lesions. As cardiovascular disease remains the leading cause of mortality globally, the role of non-invasive imaging in early detection and disease management is only expected to grow stronger.

What Role Does Technology Play in Elevating Diagnostic Accuracy and Efficiency?

Advancements in imaging technologies are central to the growing reliability and adoption of non-invasive coronary imaging solutions. The evolution of CT scanners-marked by faster acquisition speeds, reduced radiation exposure, and improved spatial resolution-has made coronary CT angiography a frontline tool for evaluating patients with suspected coronary artery disease. Simultaneously, cardiac MRI is becoming more widely used to assess myocardial perfusion, viability, and fibrosis without exposing patients to ionizing radiation. The integration of artificial intelligence and machine learning into imaging platforms is further amplifying diagnostic accuracy, allowing for automated detection of stenosis, plaque characterization, and risk stratification based on large-scale data analysis. These technologies also streamline workflow, enabling radiologists and cardiologists to interpret scans faster and with greater consistency. Dual-energy CT and photon-counting CT are the next generation of imaging innovations, providing enhanced tissue contrast and reducing artifacts that previously hindered coronary visualization. Moreover, functional imaging techniques such as stress CMR and PET scans now offer highly precise insights into myocardial blood flow and perfusion defects, which are critical for determining the need for revascularization procedures. Interoperability with electronic health records (EHRs) and cloud-based sharing systems allows for seamless data integration and second-opinion consultations across institutions. These technological leaps are not just improving accuracy-they're reshaping the diagnostic pathway to be faster, more patient-friendly, and highly personalized.

Are Shifting Clinical Practices and Patient Preferences Driving Adoption?

Changing clinical practices, along with evolving patient expectations, are playing a pivotal role in the increased demand for non-invasive coronary imaging modalities. Cardiologists and general practitioners are now more inclined to recommend non-invasive imaging as a first-line diagnostic option for stable chest pain and risk assessment, especially with the growing body of evidence supporting its clinical efficacy. Guidelines from prominent organizations such as the American College of Cardiology and the European Society of Cardiology increasingly favor non-invasive modalities due to their proven ability to reduce unnecessary invasive procedures and associated complications. From the patient's perspective, the preference for non-invasive, outpatient-based diagnostics is stronger than ever, driven by a desire for convenience, lower anxiety levels, and quicker recovery. This is particularly relevant in older populations and those with multiple comorbidities, where invasive testing poses higher risks. Non-invasive options are also more scalable in telemedicine and remote healthcare models, allowing diagnostic services to be extended to patients in rural and underserved areas. Furthermore, the rising prevalence of lifestyle-related risk factors such as diabetes, obesity, and hypertension is prompting earlier and more frequent cardiovascular screening, especially in asymptomatic high-risk groups. Hospitals and imaging centers are responding to these shifts by investing in multi-modality imaging suites and expanding cardiology service lines to accommodate outpatient diagnostics. All these trends point toward a significant shift in both provider strategy and patient mindset, reinforcing the long-term adoption of non-invasive coronary imaging across healthcare systems worldwide.

What’s Powering the Rapid Growth of the Non-Invasive Coronary Imaging Market?

The growth in the non-invasive coronary imaging market is driven by several factors spanning technological innovation, evolving clinical pathways, and shifts in healthcare delivery systems. One of the foremost drivers is the advancement of imaging platforms capable of delivering detailed, real-time visualization of coronary anatomy and function without the inherent risks of invasive procedures. Continuous improvements in scanner speed, image resolution, and post-processing software have significantly broadened the clinical utility of these modalities. On the end-user side, healthcare providers are increasingly relying on non-invasive imaging to triage patients efficiently, reduce unnecessary cardiac catheterizations, and improve overall care quality. This shift is supported by updated clinical guidelines that recognize the diagnostic and prognostic value of non-invasive techniques, particularly CCTA and cardiac MRI. Consumer behavior is also influencing market dynamics, with a growing number of patients actively seeking safer diagnostic options and participating in preventive health screening programs. Additionally, the emergence of AI-enabled imaging tools has enhanced productivity, reduced diagnostic variability, and made advanced interpretation more accessible to general practitioners and non-specialist providers. Hospital networks and imaging centers are also embracing these technologies to optimize resource utilization, shorten diagnostic timelines, and improve patient throughput. Reimbursement structures in many countries are gradually aligning with these shifts, making non-invasive imaging financially viable for providers. Finally, rising cardiovascular disease prevalence across both developed and developing nations-driven by aging populations, sedentary lifestyles, and poor dietary habits-is creating a robust and ongoing demand for accurate, early-stage diagnostic tools. Together, these factors are fueling the rapid global expansion of the non-invasive coronary imaging market.

SCOPE OF STUDY:

The report analyzes the Non-invasive Coronary Imaging market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Modality (Echocardiography, Cardiac Computed Tomography, Cardiac Magnetic Resonance Imaging, Radionuclide Cardiac Imaging); End-Use (Hospitals End-Use, Diagnostic Imaging Centers End-Use, Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â